These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1703512)

  • 1. Decay-accelerating factor regulates complement-mediated damage in the human atherosclerotic wall.
    Niculescu F; Rus HG; Vlaicu R
    Immunol Lett; 1990 Oct; 26(1):17-23. PubMed ID: 1703512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cells carrying C5b-9 complement complexes in human atherosclerotic wall.
    Rus HG; Niculescu F; PoruĊ£iu D; Ghiurca V; Vlaicu R
    Immunol Lett; 1989 Mar; 20(4):305-10. PubMed ID: 2714850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decay-accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions.
    Seifert PS; Hansson GK
    J Clin Invest; 1989 Aug; 84(2):597-604. PubMed ID: 2474572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative complement pathway-mediated myeloid cell cytotoxicity: repertoire of membrane factors participating in regulation of C3 deposition and cytolysis.
    Matsumoto M; Sugita Y; Seya T
    Eur J Immunol; 1991 Aug; 21(8):1787-92. PubMed ID: 1714391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro.
    Cheung NK; Walter EI; Smith-Mensah WH; Ratnoff WD; Tykocinski ML; Medof ME
    J Clin Invest; 1988 Apr; 81(4):1122-8. PubMed ID: 2450893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis.
    Kuraya M; Yefenof E; Klein G; Klein E
    Eur J Immunol; 1992 Jul; 22(7):1871-6. PubMed ID: 1378022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purification and characterization of decay-accelerating factor (DAF) from Raji cells.
    Fujita T; Shinkai Y; Inoue T; Tamura N
    Immunology; 1988 Jul; 64(3):369-74. PubMed ID: 2457546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decay-accelerating factor suppresses complement C3 activation and retards atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Leung VW; Yun S; Botto M; Mason JC; Malik TH; Song W; Paixao-Cavalcante D; Pickering MC; Boyle JJ; Haskard DO
    Am J Pathol; 2009 Oct; 175(4):1757-67. PubMed ID: 19729477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localization of the terminal C5b-9 complement complex in the human aortic atherosclerotic wall.
    Niculescu F; Rus H; Cristea A; Vlaicu R
    Immunol Lett; 1985; 10(2):109-14. PubMed ID: 3897036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor.
    Lederman MM; Purvis SF; Walter EI; Carey JT; Medof ME
    Proc Natl Acad Sci U S A; 1989 Jun; 86(11):4205-9. PubMed ID: 2471198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
    Iwata K; Seya T; Ariga H; Nagasawa S
    J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis.
    Niculescu F; Rus HG; Vlaicu R
    Atherosclerosis; 1987 May; 65(1-2):1-11. PubMed ID: 2955791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
    Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
    Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Test for ability of decay-accelerating factor (DAF, CD55) and CD59 to alleviate complement-mediated damage of xeno-erythrocytes.
    Miyagawa S; Shirakura R; Matsumiya G; Nakata S; Matsuda H; Hatanaka M; Matsumoto M; Kitamura H; Seya T
    Scand J Immunol; 1993 Jul; 38(1):37-44. PubMed ID: 7687071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence of human chromosome 1 with expression of human decay-accelerating factor (DAF) prevents lysis of mouse/human hybrid cells by human complement.
    Wang MW; Wright LJ; Sims MJ; White DJ
    Scand J Immunol; 1991 Dec; 34(6):771-8. PubMed ID: 1721235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decay-accelerating factor in human skin is associated with elastic fibers.
    Werth VP; Ivanov IE; Nussenzweig V
    J Invest Dermatol; 1988 Nov; 91(5):511-6. PubMed ID: 2459267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement activation induces the expression of decay-accelerating factor on human mesangial cells.
    Shibata T; Cosio FG; Birmingham DJ
    J Immunol; 1991 Dec; 147(11):3901-8. PubMed ID: 1719094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement receptors and regulatory proteins in human atherosclerotic lesions.
    Seifert PS; Hansson GK
    Arteriosclerosis; 1989; 9(6):802-11. PubMed ID: 2480105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decay accelerating factor (CD55) protects neuronal cells from chemical hypoxia-induced injury.
    Wang Y; Li Y; Dalle Lucca SL; Simovic M; Tsokos GC; Dalle Lucca JJ
    J Neuroinflammation; 2010 Apr; 7():24. PubMed ID: 20380727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque.
    Vlaicu R; Niculescu F; Rus HG; Cristea A
    Atherosclerosis; 1985 Nov; 57(2-3):163-77. PubMed ID: 3910058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.